Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Salt pills for heart failure? new study investigates

NCT ID NCT07614295

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding a small amount of salt (3 grams daily) to the diet can help people with chronic heart failure who have low blood sodium levels. Researchers will compare salt pills to a placebo in 30 adults over three months. The goal is to see if salt improves how the body handles sodium, blood pressure, and hormone activity, while also checking for safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Chronic heart failure NYHA I-III. 2. LVEF ≤40% documented in the echocardiography. 3. Stable Heart Failure symptoms: * Stable symptoms (subjectively declared by the patient) over the past three months. * No increase in peripheral edema or body weight (declared by the patient). * Loop diuretic dose equivalent to 80 mg of furosemide or 20 mg of torasemide daily, with no changes in the past three months. 4. Age over 18 and under 85 years. 5. Male or female. 6. Use of guideline-directed medical therapy (GDMT), with each drug group at maximum tolerated doses but no more than half of the maximum dose. 7. Systolic blood pressure \<100 mmHg and/or diastolic blood pressure \<60 mmHg. 8. Resting heart rate up to 80 bpm. 9. Serum sodium concentration \<140 mmol/L, regardless of the cause. Exclusion Criteria: 1. Hospitalization due to heart failure decompensation within the last three months. 2. Primary hypertrophic or restrictive cardiomyopathy, constrictive pericarditis. 3. Systemic disease known to be associated with cardiac muscle infiltration. 4. Significant valvular disease (moderate or severe stenosis of any valve, moderate or severe aortic or pulmonary regurgitation, severe tricuspid or mitral regurgitation). 5. Severe renal impairment (eGFR \<30 mL/min/1.73 m² based on the MDRD formula). 6. Stroke or transient ischemic attack (TIA) within the last three months. 7. Cardiac resynchronization therapy (CRT), ICD, ablation, or pacemaker implantation (or planned implantation) within the last three months. 8. Severe lung disease or "cor pulmonale" or other causes of isolated right ventricular failure not associated with left ventricular dysfunction. 9. Severe lung disease with respiratory failure requiring home oxygen therapy. 10. Body weight \<40 kg or ≥150 kg. 11. Life expectancy \<12 months according to the investigator's assessment 12. Pregnancy or breastfeeding. 13. Ongoing drug or alcohol abuse. 14. Lactose intolerance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic heart failure with reduced ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Heart Diseases, Wroclaw Medical University

    Wroclaw, Lower Silesian Voivodeship, 50-536, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.